Lanadelumab in Bradykinin Angioedema (KALAN)
Status
Conditions
Study type
Funder types
Identifiers
Details and patient eligibility
About
A multicenter observational study aiming to evaluate the efficacy of kallikrein inhibition by lanadelumab in patients with bradykinin- angioedema
Full description
The bradykinin-angioedema (AE-BK) is characterized by recurrent and unpredictable episodes of swelling; it can be disabling and disfiguring and the attacks affecting the larynx can be life-threatening.
The clinical symptoms depend on accumulation of bradykinin (BK), a vasoactive peptide responsible for vasodilation and increase of vascular leakage. BK formation depends on activation of the kallikrein-kinin cascade leading to uncontrolled generation of plasma kallikrein and subsequent proteolysis of high molecular-weight kininogen (HK).
Lanadelumab is a fully human monoclonal antibody inhibitor of plasma kallikrein, thereby preventing BK production; it represents an attractive therapeutic strategy for BK-AE prophylaxis.
The aim of this study is to evaluate the kallikrein inhibition by assessing the levels of cleaved HK and the immunogenicity of the lanadelumab.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Male/female >18 years old
- Patient with hereditary or acquired angioedema
- Patient treated by lanadelumab
- Patient whose the biological explorations have been carried out or will be carried out at Laboratory of Immunology of CHUGA
- Informed consent is obtained from the participant
Exclusion criteria
- Absence of biological material at T0 and M3 (stored for routine analysis)
- Person under guardianship or curatorship
- Female who is pregnant, nursing
Trial design
80 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Federica Defendi, PhD; Charlotte Kevorkian-Verguet
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal